Thymosin Beta-4 — Safety, Research, Risks & Legal Status

Not medical advice. Thymosin Beta-4 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	TB-4, thymosin-beta-4, Tβ4
Category	Peptide
natural_source	Thymus, blood plasma, wound fluid
amino_acid_count	43
related_compound	TB-500 is synthetic derivative
US legal status	Not FDA-approved for human use. Considered a research chemical and biopharmaceutical investigational agent. Not a dietary supplement. Some clinical trials are underway for heart failure and wound healing, but not approved for general use.

What is Thymosin Beta-4?

A 43-amino-acid peptide found naturally in high concentrations in thymus tissue, blood, and wound fluid. Functions as a regulatory protein that promotes angiogenesis, reduces inflammation, and supports tissue repair and remodeling.

How it works

TB-4 upregulates integrins and actin polymerization in fibroblasts, promoting cell migration and angiogenesis. It suppresses pro-inflammatory IL-6 and TNF-alpha production.

Background & history

Identified in 1981 as an abundant protein in mammalian blood and tissues. Tissue-repair properties recognized in 2000s; now under clinical investigation for cardiac and wound indications.

What the research says

Preclinical and early clinical studies report TB-4 accelerates wound healing and may support cardiac and neurological repair. Animal models show anti-inflammatory and pro-angiogenic effects. Human clinical trial data remain limited; most evidence is derived from animal models and mechanistic studies. Small pilot studies in humans show preliminary promise but require larger trials for confirmation.

Reported effects

Studied for accelerated wound and tissue healing
Reported to support angiogenesis and blood vessel formation
Researched for myocardial and cardiac function recovery
Preliminary evidence for neurological regeneration support
Animal studies suggest anti-inflammatory and immunomodulatory properties

Dosing & administration (informational)

Animal studies use doses from 1 to 50 mg/kg systemically. Clinical trials employ lower doses; optimal human dosing remains undetermined.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Limited human safety data; unknown long-term adverse profile
Injectable administration requires sterile, pharmaceutical-grade product; high contamination risk from non-GMP sources
Potential immunogenic response with repeated dosing
May interfere with wound healing in some contexts if administered incorrectly
Risk of endotoxin or bacterial contamination causing systemic inflammation

Drug & supplement interactions

May enhance effects of other angiogenic or anti-inflammatory agents
Potential interaction with anticoagulants affecting wound hemostasis
Uncertain interaction with immunosuppressive medications
May potentiate growth factor therapies in wound healing contexts

Who should avoid it

Concurrent anticoagulant use without monitoring
Administration to immunocompromised individuals without medical oversight
Non-sterile or non-pharmaceutical sources
Use in bleeding or coagulation disorders

How it is commonly combined

Combining TB-4 with growth factors (VEGF, bFGF) or other tissue-repair peptides is theoretical; safety data absent.

Legal & regulatory. Not FDA-approved for human use. Considered a research chemical and biopharmaceutical investigational agent. Not a dietary supplement. Some clinical trials are underway for heart failure and wound healing, but not approved for general use.

Quality & harm reduction

T
h
i
r
d
-
p
a
r
t
y
C
O
A
m
a
n
d
a
t
o
r
y
;
v
e
r
i
f
y
p
e
p
t
i
d
e
i
d
e
n
t
i
t
y
,
p
u
r
i
t
y
,
a
n
d
s
t
e
r
i
l
i
t
y
.
G
M
P
o
r
p
h
a
r
m
a
c
e
u
t
i
c
a
l
-
g
r
a
d
e
s
y
n
t
h
e
s
i
s
;
a
v
o
i
d
n
o
n
-
c
e
r
t
i
f
i
e
d
s
o
u
r
c
e
s
.

Lab testing & harm-reduction tools

If you are going to research a compound, verifying identity and purity is the single most protective step. Independent analytical testing and sterile-handling supplies reduce risk.

Compare testing options

Frequently asked questions

Is Thymosin Beta-4 the same as TB-500?

No. TB-500 is a synthetic derivative of TB-4 designed to be more stable and bioavailable. TB-4 is the native peptide; TB-500 is engineered for research purposes.

What does Thymosin Beta-4 do in the body?

TB-4 supports tissue repair, reduces inflammation, and promotes new blood vessel formation. It is naturally produced in high levels during wound healing and inflammation.

Can I buy pharmaceutical-grade TB-4?

TB-4 is not sold as a pharmaceutical product in most countries. It is available for research use only, and quality varies widely among suppliers.

How is Thymosin Beta-4 administered?

TB-4 is a peptide and cannot be taken orally due to digestion. It must be injected, which carries contamination risks if not from a sterile, regulated source.

Is TB-4 approved for human use?

No. TB-4 is investigational with ongoing clinical trials for heart failure and wound healing, but not yet approved for general human therapeutic use.

References & further reading

W
o
u
n
d
h
e
a
l
i
n
g
l
i
t
e
r
a
t
u
r
e
;
c
a
r
d
i
a
c
r
e
g
e
n
e
r
a
t
i
o
n
j
o
u
r
n
a
l
s
;
b
a
s
i
c
t
i
s
s
u
e
e
n
g
i
n
e
e
r
i
n
g
a
n
d
a
n
g
i
o
g
e
n
e
s
i
s
s
t
u
d
i
e
s
.